MGL-2086 / Madrigal Pharma, CSPC Pharma - LARVOL DELTA

Madrigal Pharmaceuticals Reports…Provides Corporate Updates (GlobeNewswire) - "MGL-2086 (oral GLP-1) Phase 1 trial on track to initiate in 2Q26; ervogastat/resmetirom drug-drug interaction study on track to initiate in 4Q26."

New P1 trial • New trial • Metabolic Dysfunction-Associated Steatohepatitis

…Madrigal’s MASH pipeline includes (GlobeNewswire) - "MGL-2086, an oral GLP-1 receptor agonist entering first-in-human studies in the second quarter of 2026. Ervogastat, a Phase 2 oral DGAT-2 inhibitor. The Company plans to conduct a drug-to-drug interaction study with Rezdiffra and consult with the FDA on the design of a Phase 2 combination trial this year."

FDA event • First-in-human • New trial • Metabolic Dysfunction-Associated Steatohepatitis

Closed transaction to license global rights to oral GLP-1 (MGL-2086) to combine with Rezdiffra (GlobeNewswire) - "Madrigal completed the licensing agreement with CSPC Pharma for an oral glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative....MGL-2086 (formerly SYH2086) is expected to enter the clinic in the first half of 2026."

Licensing / partnership • New trial • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited (GlobeNewswire) - "Madrigal Pharmaceuticals, Inc...announced that it has entered into an exclusive global license agreement with CSPC Pharmaceutical Group Limited (HKEX Stock CodeL 1093) ('CSPC') for SYH2086, a preclinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist and orforglipron derivative. Madrigal plans to initiate clinical development in the first half of 2026....Under the agreement, CSPC has granted Madrigal an exclusive global license to develop, manufacture, and commercialize SYH2086. CSPC will receive an upfront payment of $120 million and is eligible to receive up to $2 billion in milestone payments if certain development, regulatory and commercial milestones are achieved, as well as royalties on net sales....The transaction is anticipated to close in the fourth quarter of 2025, subject to the applicable regulatory clearance."

Licensing / partnership • Metabolic Dysfunction-Associated Steatohepatitis